<DOC>
	<DOCNO>NCT02247687</DOCNO>
	<brief_summary>Management participant low-level persistent viremia</brief_summary>
	<brief_title>Management Participants With Low-level Persistent Viremia ( ANRS 161 L-VIR )</brief_title>
	<detailed_description>ANRS 161 L-Vir phase III prospective , randomize , multicenter , open-label , superiority trial participant low-level persistent viremia . Participants randomize 1:1:1 ratio follow three arm , - Reference arm : counseling without antiretroviral treatment modification - Switch arm : switch current PI/r Prezista® ( darunavir ) / Norvir® ( ritonavir ) ( switch drug higher genetic barrier ) 600/100 mg two time day ( BID ) counseling . - Addition Isentress® ( raltégravir ) arm : Isentress® ( raltegravir ) 400 mg two time day ( BID ) add current antiretroviral treatment counseling</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age ≥ 18 year HIV1 infection On combined antiretroviral regimen least 18 month Participant stable antiretroviral regimen least 6 month , include 2 Reversetranscriptase inhibitor ( INTI ) + 1 Boosted Protease Inhibitor IP/r , participant least 2 consecutive viral load 50 500 copies/milliliter last 9 month ( least 2 month two measurement ) quantify commercial kit . 50 &lt; or= VL &lt; 500 copies/milliliter screen visit quantify commercial kit previous one . Participant naïve raltegravir ( RAL ) failure amplification successful realization genotypic resistance test without evidence resistance mutation current treatment ( 3TC/FTC accept M184V mutation ) creatinin &lt; 3 Upper Limit normal ( ULN ) Aspartate Amino Transférase ( ASAT ) , Alanine Amino Transférase ( ALAT ) &lt; 5 Upper Limit normal ( ULN ) hemoglobin &gt; 8 g/dL platelet &gt; 50 000/mm3 In woman , lack current pregnancy verify Beta Human Chorionic Gonadotropin ( βHCG ) week 4 visit use mechanical contraceptive method Informed consent Participants active health insurance coverage ( article L112111 du Code de la Santé Publique ) HIV2 infection , severe medical condition last month ( inclusion possible stable condition screen ) breastfeed woman , current pregnancy plan pregnancy within 12 month . participant currently receive Prezista® ( darunavir ) / Norvir® ( ritonavir ) ( 600/100 mg ) two time day ( BID ) ( note , participant receive Prezista® ( darunavir ) / Norvir® ( ritonavir ) one time day ( QD ) include ) Hypersensitivity Prezista® ( darunavir ) / Norvir® ( ritonavir ) excipients study treatment participant judicial protection ( judicial protection due temporarily slightly diminish mental physical faculty ) , legal guardianship plan absence could prevent patient participate trial ( travel abroad , move , pending work transfer ... )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>antiretroviral treatment</keyword>
	<keyword>viral load</keyword>
</DOC>